What 'batch testing' means for a TB-500 research peptide
Batch testing is the set of analytical procedures applied to a defined production lot to characterise its identity, purity and physical condition before the lot is released for research use. For a peptide such as TB-500, a batch is the material synthesised, purified and lyophilised together under one set of conditions and assigned a unique lot number. The certificate of analysis (CoA) is the document that records the results of these tests against pre-set acceptance criteria. Typical parameters include chromatographic purity (most commonly by RP-HPLC, reported as area percent), molecular identity (confirmed by mass spectrometry), peptide content or net peptide, and appearance. Batch-level testing matters because synthesis is inherently variable: truncated sequences, deletion products, incomplete deprotection and counter-ion or residual-solvent content can differ from lot to lot. A purity figure is only meaningful when it is tied to a stated method, column, gradient and detection wavelength, and to a specific lot. Researchers using TB-500 for in-vitro or analytical work rely on this documentation to ensure reproducibility and to attribute experimental variation to the system under study rather than to undefined material. ClaraScience publishes batch documentation so that the analytical basis of each lot is transparent and traceable. This page is research-use information only and makes no claims regarding effects in humans or animals.
RP-HPLC purity analysis of TB-500
Reversed-phase HPLC is the primary technique for assessing the chromatographic purity of synthetic peptides. The peptide is dissolved in an aqueous mobile phase and separated on a hydrophobic stationary phase — commonly a C18 column — using a gradient of water and acetonitrile, each modified with an ion-pairing additive such as trifluoroacetic acid. Components elute according to hydrophobicity, and UV detection (typically near 214 nm, where the peptide bond absorbs, and sometimes 280 nm) generates a chromatogram. Purity is reported as the area of the main peak as a percentage of total integrated peak area. Related impurities — deletion or truncation sequences, oxidised forms and synthesis by-products — appear as resolved peaks and are quantified or noted. Method parameters that must be documented for the result to be interpretable include column chemistry and dimensions, gradient profile, flow rate, injection volume, detection wavelength and run time. One published consideration specific to peptides of this class is adsorptive loss to surfaces during sample preparation, which can bias quantification if not controlled; this has been characterised for doping-relevant peptides including TB-500 (PMID 28887173). Robust RP-HPLC methods therefore standardise diluents, vials and contact materials to minimise such effects. A single purity number without an accompanying method and chromatogram is not independently verifiable.
Confirming identity by LC-MS
HPLC area-percent purity describes how much of the sample is the main component, but it does not by itself prove that the main component is the intended sequence. Mass spectrometry, usually hyphenated to liquid chromatography (LC-MS), supplies the orthogonal identity confirmation by measuring the molecular mass of the eluting species and, in tandem MS, characteristic fragment ions. For TB-500-related material, liquid chromatography-mass spectrometry approaches have been described in the analytical literature for detecting and characterising the peptide and its fragments in biological matrices (PMID 23084823; PMID 24906629). Detailed structural characterisation of the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500 products has also been published, illustrating how synthetic and modified forms are distinguished analytically (PMID 22962027). For a research CoA, the relevant outputs are the observed monoisotopic or average mass and its agreement with the theoretical mass of the target sequence. Together, RP-HPLC (purity) and LC-MS (identity) form the minimum analytical pairing that allows a batch to be described as both pure and correctly identified. Neither technique speaks to biological activity, and ClaraScience makes no such claims; the analyses establish chemical identity and purity for research-use characterisation only.
Reading a TB-500 certificate of analysis
A useful CoA lets a researcher reconstruct how each figure was produced. For a TB-500 lot, look for: the lot number and a clear product identity (sequence or reference to the thymosin beta-4 fragment); the HPLC purity value together with the method, column, gradient and detection wavelength; an attached or referenced chromatogram; the mass-spectrometry result confirming identity against the theoretical mass; peptide content or net peptide where determined; appearance; and storage and handling guidance. The presence of a stated method and an actual chromatogram distinguishes a substantive CoA from a generic figure. Cross-checking the lot number on the document against the lot on the supplied vial is a basic traceability control. Researchers should also note the analytical date and any stability or retest information, since purity can change with storage conditions over time. For step-by-step guidance, see our companion resources on how to read a CoA and on documentation and traceability. This material is provided for research-use evaluation of analytical documentation only; it is not guidance for use in humans and contains no efficacy or benefit claims.
Regulatory and research-context notes for Australia
In Australia, peptides are handled within established regulatory frameworks, and material supplied for laboratory research is positioned as research-use-only rather than for human or veterinary use. Several review articles in the orthopaedic, sports-medicine and gerontology literature discuss peptides — including thymosin beta-4-related compounds — in the context of approval status, analytical challenges and the distinction between approved and unapproved agents (PMID 41476424; PMID 41490200; PMID 41966639; PMID 42021992). These reviews underscore why analytical documentation and clear research-use framing matter when sourcing peptides. For researchers, the practical implications are procedural: confirm that batch documentation accompanies each lot, retain CoAs for audit and reproducibility, and ensure storage and handling follow the supplier's stated parameters. ClaraScience supplies TB-500 strictly for research purposes and does not provide preparation, quantity or usage instructions, and does not represent the material as suitable for human or animal use. The focus of this page is analytical chemistry, identity, purity and documentation — the technical foundations on which credible research-peptide supply rests.
Frequently asked questions
What does HPLC purity tell you about a TB-500 batch?
RP-HPLC purity is the area of the main chromatographic peak expressed as a percentage of total integrated peak area, under a stated method. It indicates how much of the sample is the principal component relative to resolved impurities, but it must be read alongside the method details and, ideally, the chromatogram. It does not by itself confirm sequence identity — that requires mass spectrometry.
Why is mass spectrometry used in addition to HPLC?
HPLC purity quantifies how much main component is present, while mass spectrometry confirms that the component is the intended molecule by measuring its mass against the theoretical value. Using both provides orthogonal evidence of purity and identity. Published LC-MS methods describe characterisation of TB-500-related peptides (PMID 23084823; PMID 22962027).
What should a TB-500 certificate of analysis include?
A substantive CoA includes the lot number, product identity, HPLC purity with the method and detection wavelength, a chromatogram, a mass-spectrometry identity result, peptide content where determined, appearance, and storage and handling notes. Matching the lot number on the document to the vial is a basic traceability check.
Is TB-500 from ClaraScience supplied for use in humans?
No. TB-500 is supplied strictly for laboratory research use. ClaraScience provides analytical documentation describing identity and purity and makes no claims about effects in humans or animals, and provides no preparation or usage instructions.
References
- PubMed PMID:23084823 — Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry — 2012
- PubMed PMID:28887173 — Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5 — 2017
- PubMed PMID:24906629 — Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls — 2014
- PubMed PMID:22962027 — Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential — 2012
- PubMed PMID:41476424 — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — 2026
- PubMed PMID:41490200 — Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — 2026
- PubMed PMID:41966639 — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — 2026
- PubMed PMID:42021992 — Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — 2026
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
